Effective inhibition of xenografts of hepatocellular carcinoma (hepg2) by rapamycin and bevacizumab in an intrahepatic model

Molecular Imaging and Biology

Volumn 11, Issue 5, 2009, Pages 334-342

  Ong, Lai Chun ^a   Song, In Chin ^a   Jin, Yi ^a   Kee, Irene H C ^a   Siew, Eeyan ^a   Yu, Sidney ^a   Thng, Choon Hua ^b   Huynh, Hung ^b   Chow, Pierce K H ^a,b,c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

18F FDG PET; Bevacizumab; Hepatocellular carcinoma; Micro CT; Micro PET; Orthotopic xenograft model; Rapamycin; Tumor vasculature

Indexed keywords

BEVACIZUMAB; CD31 ANTIGEN; FLUORODEOXYGLUCOSE F 18; RAPAMYCIN; VASCULOTROPIN;

ABDOMINAL SWELLING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN HEPG2; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DISEASE PROGRESSION; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MICE; POSITRON-EMISSION TOMOGRAPHY; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; X-RAY MICROTOMOGRAPHY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MAMMALIA; MUS;

EID: 68449103037     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-009-0213-4     Document Type: Article

References (38)

1. Pang R, Poon RT (2006) Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 242:151-167
2. Parkin DM, Bray F, Ferlay J, Pisani P (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153-156
3. Llovet JM (2004) Treatment of hepatocellular carcinoma. Curr Treat Options Gastroenterol 7:431-441
4. Poon RT, Fan ST (2004) Resection prior to liver transplantation for hepatocellular carcinoma: A strategy of optimizing the role of resection and transplantation in cirrhotic patients with preserved liver function. Liver Transpl 10:813-815
5. Nowak AK, Chow PK, Findlay M (2004) Systemic therapy for advanced hepatocellular carcinoma: A review. Eur J Cancer 40:1474-1484
6. Rao RD, Buckner JC, Sarkaria JN (2004) Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents. Curr Cancer Drug Targets 4:621-635
7. Fingar DC, Blenis J (2004) Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23:3151-3171
8. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24:200-216
9. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M et al (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 8:128-135
10. McCarthy M (2003) Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet 361:1959
11. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434
12. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727-739
13. Sausville EA, Burger AM (2006) Contributions of human tumor xenografts to anticancer drug development. Cancer Res 66:3351-3354, discussion 3354
14. Teicher BA (2006) Tumor models for efficacy determination. Mol Cancer Ther 5:2435-2443
15. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S et al (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84:1424-1431
16. Chang CJ, Tai KF, Roffler S, Hwang LH (2004) The immunization site of cytokine-secreting tumor cell vaccines influences the trafficking of tumor-specific T lymphocytes and antitumor efficacy against regional tumors. J Immunol 173:6025-6032
17. Bibby MC (2004) Orthotopic models of cancer for preclinical drug evaluation: Advantages and disadvantages. Eur J Cancer 40:852-857
18. Wahl RL, Hutchins GD, Buchsbaum DJ, Liebert M, Grossman HB, Fisher S (1991) 18F-2-deoxy-2-fluoro-d-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. Cancer 67:1544-1550
19. Strauss LG, Conti PS (1991) The applications of PET in clinical oncology. J Nucl Med 32:623-648, discussion 649-650
20. Deroose CM, De A, Loening AM, Chow PL, Ray P, Chatziioannou AF et al (2007) Multimodality imaging of tumor xenografts and metastases in mice with combined small-animal PET, small-animal CT, and bioluminescence imaging. J Nucl Med 48:295-303
21. Jeng LB, Changlai SP, Shen YY, Lin CC, Tsai CH, Kao CH (2003) Limited value of 18F-2-deoxyglucose positron emission tomography to detect hepatocellular carcinoma in hepatitis B virus carriers. Hepatogastroenterology 50:2154-2156
22. Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H et al (2000) Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 32:792-797
23. Ho CL, Chen S, Yeung DW, Cheng TK (2007) Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 48:902-909
24. Atkin G, Barber PR, Vojnovic B, Daley FM, Glynne-Jones R, Wilson GD (2005) Correlation of spectral imaging and visual grading for the quantification of thymidylate synthase protein expression in rectal cancer. Hum Pathol 36:1302-1308
25. Park YN, Kim YB, Yang KM, Park C (2000) Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 124:1061-1065
26. An FQ, Matsuda M, Fujii H, Matsumoto Y (2000) Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma. J Cancer Res Clin Oncol 126:153-160
27. Eskens FA, Verweij J (2006) The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 42:3127-3139
28. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027
29. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191
30. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E et al (2005) Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502-3508
31. Semela D, Piguet AC, Kolev M, Schmitter K, Hlushchuk R, Djonov V et al (2007) Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 46:840-848
32. Torimura T, Sata M, Ueno T, Kin M, Tsuji R, Suzaku K et al (1998) Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 29:986-991
33. Sun L, Wu H, Pan WM, Guan YS (2007) Positron emission tomography/ computed tomography with (18)F-fluorodeoxyglucose identifies tumor growth or thrombosis in the portal vein with hepatocellular carcinoma. World J Gastroenterol 13:4529-4532
34. Giannelli G, Fransvea E, Trerotoli P, Beaugrand M, Marinosci F, Lupo L et al (2007) Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim Acta 383:147-152
35. Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB (2002) Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 36:410-417
36. Cedrone A, Covino M, Caturelli E, Pompili M, Lorenzelli G, Villani MR et al (2000) Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: Does different viral etiology influence AFP levels in HCC? A study in 350 western patients. Hepatogastroenterology 47:1654-1658
37. Marrero JA, Lok AS (2004) Newer markers for hepatocellular carcinoma. Gastroenterology 127:S113-S119
38. von Schulthess GK, Steinert HC, Hany TF (2006) Integrated PET/CT: current applications and future directions. Radiology 238:405-422